Home » Biocad Said to Seek Buyer in Sale That May Top $1 Billion
Biocad Said to Seek Buyer in Sale That May Top $1 Billion
Pfizer and Amgen are two bidders still in the race to buy Biocad, a Russian pharmaceutical company that attempts to produce biosimilars of cancer drugs.
Bloomberg
Bloomberg
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May